Intelligent Classifier: a Tool to Impel Drug Technology Transfer from Academia to Industry

Lin, Hui-Heng; Ouyang, Defang; Y, Hu

doi:10.1007/s12247-018-9332-2

Cited by 4 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multilayer neural networks were developed in order to identify the trends of specific pharmaceutical technologies' emergingness. Similarly, Lin et al have created a SVMbased classifier for the prediction of the licensing outcomes of pharmaceutical patents held by universities(35).…”

mentioning

confidence: 99%

Review of machine learning algorithms' application in pharmaceutical technology

Đuriš¹,

Kurćubić²,

Ibrić³

2021

Arhiv za farmaciju

View full text Add to dashboard Cite

Machine learning algorithms, and artificial intelligence in general, have a wide range of applications in the field of pharmaceutical technology. Starting from the formulation development, through a great potential for integration within the Quality by design framework, these data science tools provide a better understanding of the pharmaceutical formulations and respective processing. Machine learning algorithms can be especially helpful with the analysis of the large volume of data generated by the Process analytical technologies. This paper provides a brief explanation of the artificial neural networks, as one of the most frequently used machine learning algorithms. The process of the network training and testing is described and accompanied with illustrative examples of machine learning tools applied in the context of pharmaceutical formulation development and related technologies, as well as an overview of the future trends. Recently published studies on more sophisticated methods, such as deep neural networks and light gradient boosting machine algorithm, have been described. The interested reader is also referred to several official documents (guidelines) that pave the way for a more structured representation of the machine learning models in their prospective submissions to the regulatory bodies.

show abstract

mentioning

confidence: 99%